Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $11.7 million.

  • Eton Pharmaceuticals' Free Cash Flow rose 29776.42% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.0 million, marking a year-over-year increase of 89734.22%. This contributed to the annual value of $943000.0 for FY2024, which is 8616.29% down from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Free Cash Flow stood at $11.7 million, which was up 29776.42% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Free Cash Flow ranged from a high of $11.7 million in Q3 2025 and a low of -$5.1 million during Q4 2021
  • Over the past 5 years, Eton Pharmaceuticals' median Free Cash Flow value was $1.2 million (recorded in 2022), while the average stood at $1.6 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 76395.66% in 2022, then plummeted by 30077.52% in 2024.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Free Cash Flow stood at -$5.1 million in 2021, then surged by 155.22% to $2.8 million in 2022, then tumbled by 86.32% to $387000.0 in 2023, then plummeted by 300.78% to -$777000.0 in 2024, then soared by 1611.2% to $11.7 million in 2025.
  • Its Free Cash Flow stands at $11.7 million for Q3 2025, versus $8.0 million for Q2 2025 and $2.1 million for Q1 2025.